홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
SLS
#2555
SELLAS Life Sciences Group, Inc. Common Stock
4.8
9
USD
+0.62%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+0.62%
월간 변동
-10.28%
6달 변화
+116.37%
년간 변동율
+276.15%
이전 종가
4.8
6
Open
4.8
7
Bid
Ask
Low
4.8
7
High
4.9
2
양
387
마켓
주식
헬스케어
SLS
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
90.85 M
99.78 M
105.3 M
142.44 M
179.58 M
—
Valuation ratios
Enterprise value
80.59 M
79.36 M
205.3 M
185.01 M
605.23 M
1.07 B
Price to earnings ratio
-2.08
-3
-7.3
-6.19
-15.08
-31.57
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-1.8
-2.15
-5.36
-4.47
-14.48
-26.46
Price to book ratio
6.72
1.43
2.26
1.39
5.8
10.88
EBITDA 비율에 대한 기업 가치
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.35
-0.17
-0.2
-0.13
-0.1
-0.6
Return on equity %
-0.71
-0.21
-0.25
-0.15
-0.11
-0.72
Return on invested capital %
—
—
—
—
-844.75
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
1.72
4.64
4.91
8.28
10.72
28.55
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.12
-0.1
-0.07
-0.07
-0.05
-0.29
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
0.23
0.32
0.26
0.41
0.66
1.65
Net current asset value per share
0.27
0.36
0.3
0.45
0.69
1.81
Tangible book value per share
0.12
0.29
0.25
0.4
0.63
1.58
Working capital per share
0.11
0.29
0.24
0.4
0.63
1.55
Book value per share
0.15
0.32
0.27
0.42
0.65
1.65
뉴스
SELLAS, 2상 AML 임상시험 첫 환자 등록
SELLAS enrolls first patient in Phase 2 AML trial of SLS009
셀라스 생명과학, 워런트 행사로 4,260만 달러 조달
Sellas Life Sciences reports $42.6 million in warrant exercise proceeds
What's Going With SELLAS Life Sciences Stock On Wednesday? - SELLAS Life Sciences Gr (NASDAQ:SLS)
H.C. Wainwright, Solaris Resources 목표 주가 16달러로 상향
H.C. Wainwright raises Solaris Resources stock price target to $16 on Warintza progress
Why I’m Selling Sellas Life Sciences Ahead Of The REGAL Reveal (NASDAQ:SLS)
Solaris Resources, 52주 신고가 $8.54 기록
SELLAS, 유럽서 SLS009 임상시험 위해 IMPACT-AML과 협력
SELLAS partners with IMPACT-AML for European SLS009 trials
Lam Research, Micron Tech among market cap stock movers on Tuesday